Brief: Valneva Responds To Chikungunya Outbreak In La Réunion With Vaccine
24/03/2025 06:04
March 24 (Reuters) - Valneva SE VLS.PA: RESPONDS TO CHIKUNGUNYA OUTBREAK IN LA RÉUNION WITH VACCINE FRENCH AUTHORITIES TO PAY FOR 40,000 DOSES OF CHIKUNGUNYA VACCINE IN APRIL CHIKUNGUNYA CASES IN LA RÉUNION REACH 8,600 WITH 3,000 NEW CASES IN A WEEK IXCHIQ IS WORLD'S FIRST LICENSED CHIKUNGUNYA VACCINE Source text: ID:nGNE7kpXsw Further company coverage: VLS.PA (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Valneva SE
See all newsBrief: UK MHRA Withdraws Marketing Authorisation for Ixchiq Chikungunya Vaccine After Safety Review
Valneva falls as UK regulator revokes Ixchiq vaccine authorisation
Brief: Valneva Provides Update On Ixchiq® In The United Kingdom
Valneva surges after EU regulator validates Lyme disease vaccine application
Brief: Pfizer And Valneva's Lyme Disease Vaccine Candidate Marketing Authorization Application Validated By European Medicines Agency